Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma

Yu Kyoung Cho, MS, Junan Li, PhD, Douglas W. Sborov, MD, Jiang Wang, PhD, Yue Gao, PhD, Misty Lamprecht, CNS, Ming Poi, PharmD, PhD, Mitch A. Phelps, PhD, Craig C Hofmeister, MD MPH

Blood (2014) 124 (21): 1086.

https://doi.org/10.1182/blood.V124.21.1086.1086

Published: 2014

Journal Articles

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Rajeswaran Mani, DVM, Yicheng Mao, PhD, Frank W Frissora, M.S., Chi-ling Chiang, Jiang Wang, Yuan Zhao, Yun Wu, Bo Yu, Ph.D., Ribai Yan, Xiaokui Mo, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, Ph.D., Mitch A. Phelps, PhD, Robert J. Lee, Ph.D, Ching-Shih Chen, PhD, James Lee, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2013) 122 (21): 4168.

https://doi.org/10.1182/blood.V122.21.4168.4168

Published: 2013

Journal Articles

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Hongyan Wang, Ping Chen, Ph.D., Jiang Wang, Ramasamy Santhanam, Ph.D, Josephine Aimiuwu, Vijayasaradhi UV, Zhongfa Liu, Sebastian Schwind, MD, Alice S. Mims, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Michael R. Grever, MD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Ramiro Garzon, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3578.

https://doi.org/10.1182/blood.V120.21.3578.3578

Published: 2012

Journal Articles

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Rebecca B Klisovic, MD, Hongyan Wang, Alison Walker, MD, Katherine Walsh, MD, Sumithira Vasu, MBBS, Ramiro Garzon, MD, Steven M. Devine, MD, Jiang Wang, Celia Garr, RN, Adam Norris, John C. Byrd, MD, Michael R. Grever, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3616.

https://doi.org/10.1182/blood.V120.21.3616.3616

Published: 2012

Journal Articles

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

William Blum, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Sebastian Schwind, MD, Yao Jiang, Jiang Wang, Mitch Phelps, PhD, Susan Geyer, PhD, Steven M. Devine, MD, Kathy Walsh, MD, Sumithira Vasu, MBBS, John P. Curfman, Larry Schaaf, PhD, Celia Garr, RN, Cheryl Kefauver, RN, John C. Byrd, MD, Michael R. Grever, MD, Ramiro Garzon, MD, Guido Marcucci, MD

Blood (2012) 120 (21): 2619.

https://doi.org/10.1182/blood.V120.21.2619.2619

Published: 2012

Journal Articles

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Josephine Aimiuwu, Hongyan Wang, Ping Chen, Zhiliang Xie, Jiang Wang, Shujun Liu, Rebecca Klisovic, Alice Mims, William Blum, Guido Marcucci, Kenneth K. Chan

Blood (2012) 119 (22): 5229–5238.

https://doi.org/10.1182/blood-2011-11-382226

Published: 2012

Includes: Supplemental data

NARROW

Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only